Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, December 6, 2022
[ Tue, Dec 06th 2022
] - WOPRAI
Mon, December 5, 2022
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
[ Mon, Dec 05th 2022
] - WOPRAI
Chris Shibutani Initiated (UTHR) at Strong Sell and Held Target at $230 on, Dec 5th, 2022
Chris Shibutani of Goldman Sachs, Initiated "United Therapeutics Corporation" (UTHR) at Strong Sell and Held Target at $230 on, Dec 5th, 2022.
Chris has made no other calls on UTHR in the last 4 months.
There are 4 other peers that have a rating on UTHR. Out of the 4 peers that are also analyzing UTHR, 0 agree with Chris's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Chris
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $300 on, Thursday, November 3rd, 2022
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $375 on, Thursday, November 3rd, 2022
- Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $265 on, Thursday, November 3rd, 2022
- Terence Flynn of "Morgan Stanley" Maintained at Buy with Increased Target to $322 on, Thursday, November 3rd, 2022
